PCMC
GPCR icon

Planning Capital Management Corporation’s Structure Therapeutics GPCR Stock Holding History

Planning Capital Management Corporation’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.76K Hold
40
– – ﹤0.01% 601
2024
Q2 		$1.57K Sell
40
-100
-71% -$4.11K ﹤0.01% 557
2024
Q1 		$6K Hold
140
– – ﹤0.01% 465
2023
Q4 		$5.71K Buy
+140
New +$8.02K ﹤0.01% 466

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Planning Capital Management Corporation's GPCR Position: Q3 2024 in Review

Planning Capital Management Corporation held its Structure Therapeutics (GPCR) position steady in Q3 2024 at 40 shares worth $1.76K. The position accounts for ﹤0.01% of the portfolio, ranked #601.

Planning Capital Management Corporation first reported a position in GPCR in Q4 2023 and has held it in 4 quarters since. The position peaked at $6K in Q1 2024. 160 funds tracked by Wall St. Rank hold GPCR as of Q3 2024.

  • Planning Capital Management Corporation held 40 shares of Structure Therapeutics worth $1.76K as of Q3 2024.
  • Planning Capital Management Corporation left its Structure Therapeutics share count unchanged in Q3 2024.
  • Structure Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #601 holding.
  • Planning Capital Management Corporation first reported a position in Structure Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • Planning Capital Management Corporation's Structure Therapeutics position peaked at $6K in Q1 2024.
  • 160 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.